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ABSTRACT
JAMIE STONE: The Evaluation of AZ66, A Highly Selective Sigma-1 and Sigma-2 Antagonist, for
Anticonvulsive Effects in C57Bl/6 Mice
(Under the direction of Lisa Wilson and Dr. Christopher McCurdy)

Sigma receptors have become a popular subject for research the past few decades, but
there is still much mystery behind these receptors and how they work. Researchers have found
that sigma receptor antagonists can attenuate cocaine induced convulsions, however, limited
research has been conducted on the effects of these antagonists on convulsions that mimic the
types of seizures associated with epilepsy. Therefore, the aim of the current study was to
evaluate AZ66 (20 mg/kg i.p.), a highly selective sigma 1 & 2 receptor antagonist, against
pentylenetetrazole (PTZ) (80 mg/kg s.c.) induced convulsions. The first aim of the study was to
determine the optimal dose and dosing method for the administration of PTZ in our
laboratories. Both subcutaneous (s.c.) and intraperitoneal (i.p.) injections were separately
investigated at 50-80 mg/kg and 30-60 mg/kg doses respectively. The second aim was to find
the minimum dose of AZ66 that was effective at reducing or attenuating PTZ induced
convulsions. The AZ66 dose was administered one hour before the PTZ dose administration.
Seizure latency and frequency were recorded. The subcutaneous 80 mg/kg dose of PTZ was
chosen due to its fast response time and clear distinction between seizures. AZ66 decreased
seizure latency and increased seizure frequency and resulted in death when given at the
30mg/kg dose. Further studies on the role of the sigma receptors in epilepsy are needed.
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I.

Background
Epilepsy is a debilitating disease that affects over 2.4 million adults and 450,000 children

in the United States alone ("Hope Through Research", 2016). This chronic disorder is
recognized by the World Health Organization (WHO) as one of the most common neurological
diseases worldwide (“Epilepsy Fact Sheet” 2016). Perhaps the most alarming thing about
epilepsy is that anyone can develop it regardless of sex, age, or ethnic background. Caused by
an unbalance of hyperactive electrical signals in the brain, epilepsy is commonly characterized
by unpredictable and frequent seizures.
While epilepsy is a disorder of multiple seizures over a period of time longer than
twenty-four hours, a seizure is a single occurrence. Seizures can be classified into two broad
categories: generalized and focal/partial. Generalized seizures affect the whole brain while
focal/partial seizures affect only a specific part. Generalized seizures are commonly described
by a loss of consciousness and motor control. This type of seizure is further classified into
either tonic-clonic, absence, or atonic seizures depending on the symptoms that manifest.
Tonic-clonic seizures, formerly known as grand mal seizures, are distinguishable by their jerklike contractions of the whole body and long recovery time. This type of generalized seizure is
typically long in duration and can last for several minutes. Another type of generalized seizures
is the absence seizure, also known as the petit mal seizure. This category of seizures is defined
by the person being unable to control his or her body position. These seizures look similar to
tonic clonic seizures, however the duration of the seizure is much shorter and the recovery time
is faster. Atonic seizures refer to generalized seizures in which the patient’s muscles suddenly

become limp and unexpectedly drop to the ground. These seizures are also referred to as drop
attacks and often result in injury (“Types of Seizures”, 2016).
Unlike generalized seizures, in focal/partial seizures consciousness is not lost and the
region of the brain affected is limited to a particular area. The affected area of the brain
determines the classification of the simple partial seizure as well as the manifestation of the
symptoms. These seizures can affect specific motor functions, blood pressure and heart rate,
parts of the brain that trigger emotions, and result in sensory hallucinations. Often times, a
simple partial seizure will start in one area of the brain and move to another; this results in a
complex partial seizure. This type of seizure is distinguished by an altered state of
consciousness not seen in simple partial seizures. People diagnosed with complex partial
seizures report experiencing staring blankly into space or performing repetitive, non-purposeful
tasks. As a whole, epilepsy displays a distinct combination of seizures specific to the individual
patient (“Types of Seizures”, 2016). This makes each disease unique to the individual and
oftentimes creates difficulties in diagnosing and treating epilepsy.
The National Institute of Neurological Disorders and Stroke (NINDS) considers a person
to be epileptic if they have two or more seizures occurring over a time period longer than
twenty-four hours ("Hope Through Research", 2016). There are many individualized aspects to
epilepsy including the cause, type, and severity of the seizures that contribute to the specificity
of the disease. It is imperative to understand and consider these aspects when determining the
appropriate treatment plan. In the book The Epilepsies: Seizures, Syndromes and Management,
Panayiotopoulos highlights 3 important diagnostic steps that doctors follow in order to
determine the correct therapy (Panayiotopoulos 2005). First, it is important to know that the

seizures are not a result of an underlying, curable illness. Seizures can be caused by a number
of disorders including a high fever, a buildup of toxins, abnormal glucose levels, or a brain
infection (Shelat, 2015). If a patient is incorrectly diagnosed with epilepsy, then they are being
denied lifesaving medical care. As a result, doctors need to exhaust all diagnostic tests before
concluding that a person has epilepsy. If the seizures are determined to be caused by epilepsy,
doctors then ascertain the type of seizures being presented. This step ensures later on that the
treatment selected will be tailored for the individual patient. Finally, after the type of seizure is
established, then the epileptic syndrome can be diagnosed. This ensures an accurate and
personalized treatment for each patient. Currently, there is no cure for epilepsy but it can be
controlled with medication and other lifestyle changes. About 50% of seizures are completely
controlled using anti-epileptic drugs (AEDs) and an additional 25% of patients drastically
improve (Goldenberg MM, 2010). Along with medication, doctors also implement lifestyle
changes such as diet and exercise as part of a holistic treatment plan. The goal is to prevent
seizures and improve the patient’s quality of life.
As of now, there are only 26 anti-epileptic drugs currently on the market. These drugs
produce a host of side effects that range from drowsiness to a loss of coordination or memory,
and even death ("List of Anti-Epileptic Drugs", 2014). In order to generate new antiepileptic
medications, NINDS created a program that tests compounds for anti-seizure activity called the
Epilepsy Therapy Screening Program (ETSP) formerly called the Anticonvulsant Screening
Program (ASP). One of the main focuses of this program is to identify potential therapeutic
agents that could be used to treat epilepsy ("Epilepsy Therapy Screening Program" 2017).
When a compound is submitted to the ETSP, its structure is compared to a large internal

database to help determine any structure-activity relationships and to ensure that the
compound is chemically unique. NINDS uses well established rodent seizure models to screen
in four categories: Standard Anti-Ictal Screening, Models of Pharmacoresistance,
Identification/Differentiation, and Screening for Related Indications. These four areas test the
compound’s efficacy in treating specific seizure types, determining its effect on the seizure
thresholds, and if treats related medical comorbidities.
The Maximal Electric Shock (MES) is a standard Anti-Ictal Screening model used to mimic
generalized tonic-clonic seizures. This type of test involves an electric shock to see if the
compound will prevent the seizure from occurring when all neuronal circuits in the brain are
maximally active. In order to test a substance’s ability to treat complex partial seizures, the
Kindled Rat Model is employed. This model can also be modified to include a simulation of
pharmacoresistance. About 30% of epileptic patients are resistant to traditional anti-seizure
drugs (Brodie, Kwan, 2002), so this analysis is a useful way to identify compounds that
demonstrate an ability to treat therapy resistant epilepsies. Classified under
Identification/Differentiation, the Intravenous Pentylenetetrazole (Metrazol, PTZ) Seizure
Threshold Test determines the compounds ability to change the seizure threshold. PTZ is
intravenously injected into the rat to produce a chemically induced seizure. If the compound
lowers the seizure threshold, then it is considered to be pro-convulsant because the number of
seizures increases. Likewise, if the compound decreases the number of seizures it is an
anticonvulsant because the substance raised the seizure threshold. The Intravenous PTZ
Seizure Threshold Test is a staple in testing potential new anti-seizure medications because it
quickly identifies if the compound is counter-effective. Finally, the Mouse Formalin Test of

Hyperalgesia screens for a substance’s ability to also treat pain related to epilepsy. This
particular model determines if the compound being tested reduces acute and inflammatory
pain in the mouse. This test is important because patients, in addition to having seizures, often
have to deal with the comorbidities of epilepsy or the side effects of the treatment that affect
their quality of life (Kerr, 2012).
Due to the numerous side effects and the limited number of drugs on the market, many
patients are seeking alternative forms of therapies. These alternative therapies are often used a
last resort when approved forms of medication fail. Among these alternative therapies “herbal
remedies are used as first line treatments for all illnesses in an estimated 80% of the world’s
population” (Kneen, Appleton, 2006). Unfortunately, these nonconventional AEDs are further
encouraged by the media with little or no evidence based support and require further
investigation to determine the effectiveness of such treatment plans.
One such alternative treatment for epilepsy is marijuana, also known as cannabis.
Specifically, there are two compounds of interest in marijuana: cannabidiol (CBD) and
tetrahydrocannabinol (THC). These two compounds are both known for their anti-convulsant
effects in the MES model of epilepsy, but only THC exerts its effects through the
endocannabinoid system. CBD’s mechanism of action is still unclear. Interestingly, CBD and
THC are suggested to have a synergistic relationship in their anticonvulsant properties due to
CBD’s mechanisms of action (Szaflarski et al., 2014). The ratio of CBD to THC may determine
the effectiveness of treating seizures while minimizing the psychoactive effects associated with
marijuana. One study found that cannabis containing high concentrations of CBD and low
concentrations of tetrahydrocannabinol (THC) was very effective as an anticonvulsant in animal

models (Szaflarski et al., 2014). While medical marijuana use has been dated back to China
approximately 2500 BC (Jiang et al., 2006), there is only circumstantial evidence of its
effectiveness to treat epilepsy because it is still unclear how marijuana exerts its anti-epileptic
properties (Szaflarski et al., 2014). Nevertheless, cannabidiol has recently gained popularity
with the general public as a potential medication for drug resistant epilepsies. Capitalizing on
this popularity, GW Pharmaceuticals announced a new experimental drug that, if approved by
the Food and Drug Administration (FDA), will be the first marijuana based prescription drug in
the United States (Pollack, 2016). Epidiolex contains cannabidiol and is currently showing
promising results in treating Dravet Syndrome during phase 3 clinical trials (Pollack, 2016).
During this phase, the effectiveness of the drug is statistically calculated against a placebo.
After undergoing multiple tests, the FDA can then decide whether or not to approve the drug
for sale. Dravet syndrome is a childhood epilepsy known for its resistance to drug therapy. If
Epidiolex is approved by the FDA, it could prove to be a major breakthrough in treating
intractable epilepsies. While the results of this trial look promising, it is still unknown how
cannabidiol exerts its antiepileptic properties or its long term effects.
Because CBD is a schedule 1 drug, illegal due to its high potential for abuse, no currently
accepted medical use, and safety concerns, it is important to seek alternative treatments for
epilepsy. Sigma receptors could prove to be that alternative treatment. Sigma receptors were
once thought to be a class of opioids receptors due to the initial compounds that had opioidlike effects and unique effects that could not be reversed by standard opioid antagonists
(Martin, 1976). However, it was later proven to be a separate class of receptors with a selective
drug pattern and distinct anatomical distribution. For example, sigma receptors have a high

affinity for (+) benzomorphans, whereas opioid receptors selectively prefer (-) benzomorphans,
and were found to produce effects unaffected by opioid antagonists. Sigma receptors interact
with a diverse set of compounds including opiates, neuroleptics, antihistamines, and
antidepressants. There are two distinct subtypes of sigma receptors. Sigma-1 receptors are
expressed more dominantly over sigma-2 and are slightly larger in size. Sigma-1 receptors are
also known to translocate during signaling and are associated with regulating intracellular
secondary messengers. So far, only the sigma-1 receptor has been sequenced and cloned from
a variety of different species, including humans. The identity of the sigma-2 receptor is still
unknown and is under current debate. However, there is strong evidence that the sigma-2
receptor is a unique protein that resides in lipid rafts (Chu, et al. 2015). Currently, we do not
know of any purely selective sigma-2 compounds. Sigma compounds that interact with
receptors either non-selectively bind with either sigma-1 or sigma-2, or solely sigma-1
receptors. The sigma agonists and antagonist that are frequently utilized in research and have
a higher affinity for sigma-2 receptors (over sigma-1 receptors) also bind with opioid receptors.
Sigma receptors as a whole are found throughout the body. The highest concentration of sigma
receptors is found in the brain and spinal cord, most notably in the brainstem motor nuclei.
This suggests that sigma receptors play a significant role in motor function and control. Sigma
receptors are also found throughout the body in peripheral organs suggesting that perform a
necessary physiological function (Matsumoto et al., 2007). Because of their widespread
distribution and concentration in motor nuclei, sigma receptors represent a potential target
towards creating new medicines and in treating numerous diseases, including epilepsy
(Maurice, Su, 2009).
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Figure 1: Structure of AZ66
AZ66 {3-[4-(4-cyclohexylpiperazin-1-yl)pentyl]-6-fluorobenzo[d] thiazole-2(3H)-one} is a
highly selective sigma-1 and sigma-2 receptor antagonist that binds with almost equal affinity
to each subtype. This synthetic compound was derived from CM156, also a sigma receptor
antagonist. AZ66 was developed for its longer half-life and an increased metabolic stability
than its precursor CM156. AZ66 has a favorable pharmacokinetic profile and is capable of being
administered orally. This novel ligand has been shown to mitigate many methamphetamineinduced behaviors (Seminerio et al., 2016) as well as attenuate cocaine induced seizures
(Matsumoto et al, 2002). Because of these properties, it is reasonable to assume that AZ66
could also be effective in reducing seizures produced by epilepsy. Until now, there have not
been any studies to determine the effects of AZ66 on seizures that mimic epilepsy. This opens
a whole new area of investigation for sigma receptor antagonists like AZ66.
This thesis aims to begin that exploration by studying AZ66’s anticonvulsive effects in PTZ
induced seizures that mimic epilepsy. PTZ is a GABAA receptor antagonist that is the gold
standard for chemically inducing seizures in anti-epileptic drug assessments (Lüttjohann,

Fabene, & Luijtelaar, 2009). To perform this evaluation, the optimal dose and dosing method of
PTZ in our laboratories needed to be assessed. From there, the minimum dose of AZ66
effective at reducing PTZ induced seizures can then be determined.

II.

Methods

Subjects
Adult male black C57BL6 mice were acquired from Harlan Laboratories and were the
subjects to complete the 2 aims. All animals were housed 5 to a cage and received food and
water ad lib. The housing facilities were maintained on a 12-hour light schedule from 6:00am
to 6:00 pm. The Institutional Animal Care and Use Committee (IACUC) approved the methods
performed in this study.
Drug Preparation
All drugs were dissolved in saline solution before administration. AZ66 was prepared
and synthesized in Dr. McCurdy’s lab as part of the Department of BioMolecular Sciences
Division of Medicinal Chemistry. Drugs were delivered to the animals by either intraperitoneal
(i.p,) or subcutaneous (s.c.) injection.
Aim 1
In order to find the optimal dosing method and dose of pentylenetetrazole (PTZ), 8 mice
for each dose and dosing method were brought into the procedure room to acclimate for 30
minutes. Afterwards the first mouse was injected with a single dose of PTZ, dissolved in normal
saline, and placed into a Plexiglas chamber. There were no more than 2 mice in each Plexiglas
chamber at one time. Normal saline was used as a negative control. Each mouse was observed

for a total time of 30 minutes, during which we watched for the appearance of tonic-clonic
seizures. Tonic-clonic seizures are characterized by the stiffening of the body followed by
spasms and jerks of the muscles. The latency period of the first major seizure and the number
of mini and major seizures that each mouse had was recorded. We defined major seizures as
having very visible tonic-clonic seizures and a slow recovery time afterwards, usually around the
minute mark or longer depending on the severity of the seizure. While mini seizures were
defined as very short, rapid convulsions in which the tonic-clonic seizure was difficult to
observe and the mice had a very rapid recovery of a few seconds.
Aim 2
After a 30 min acclamation period, during which the mice were weighed and marked,
the AZ66 compound was administered at either a 10, 20, or 30 mg/kg dose. After an hour
pretreatment of the AZ66, the mice were then treated with a subcutaneous 80 mg/kg dose of
PTZ. Then, as before in the dose response, the mice were then observed for 30 minutes and
the seizure latency and the number of mini and major seizures recorded.
Data Analysis
Data was shown as mean ± SEM. with each group having n= 8 animals. Statistical
analysis was performed using one-way ANOVA preceded by the Tukey post hoc test to define
the significant different against the vehicle control at p<.05 for each dose of PTZ and AZ66.

III.

Results

Aim 1
Figure 2 demonstrates the seizure latency for two dosing methods, intraperitoneal and
subcutaneous, at increasing doses of PTZ. The saline solution as expected did not produce a
seizure and therefore had a latency time of 30 minutes which was the total time of observation.
Every dose for each dosing method was significantly different when compared to the vehicle
with the exception of the intraperitoneal 30 mg/kg dose. The i.p. 40 mg/kg dose of PTZ differed
from the vehicle at a p-value <.005 while the other doses, with the exception of the i.p. 30
mg/kg dose of PTZ, were significantly different with p-values < .001. The dosing methods only
significantly differed between the s.c. 50 mg/kg dose compared to the i.p. 30 mg/kg dose and
the 60 mg/kg dose s.c. matched to the i.p. 40 mg/kg dose of PTZ (p<.001). The fastest latency
time was 60 mg/kg dose of PTZ administered intraperitoneally.
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Figure 2: Seizure latency of intraperitoneal and subcutaneous dosing of PTZ
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Figure 3: Average number of total seizures induced by each dose of PTZ
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Figure 4: Average number of major seizures for intraperitoneal and subcutaneous dosing of PTZ

Figure 3 represents the total number of seizures for each dose of PTZ and Figure 4 is the
average number of major seizures for each dosing method and the dose studied. The 70 mg/kg
dose administered subcutaneously and the 60 mg/kg dose administered intraperitoneally
differed significantly from the vehicle at a 95% confidence interval. There was no significant
difference between the dosing methods and the number of seizures for each comparison
group. Both figures 3-4 reflect that the 80 mg/kg subcutaneous dose of PTZ induced the most
seizures although the intraperitoneal 60 mg/kg dose was statistically comparable.
Aim 2
AZ66 did not produce any seizures or adverse side effects during the hour pretreatment.
Figure 5 relates the average seizure latency time of the different doses of AZ66 compared to
the lone 80 mg/kg dose of PTZ. All doses of AZ66 were statistically significant at a p-value <
.001 when compared to the vehicle. As the dose of AZ66 increased, the onset of the seizures
occurred more rapidly. While conducting the trial with the pretreatment of the 30 mg/kg dose
of AZ66, the experiment was stopped early when it became apparent that inducing a seizure
was fatal at this dose.
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Figure 5: Average seizure latency time for doses of AZ66
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Figure 6: Average number of total seizures for each dose of AZ66 with PTZ (80mg/kg s.c.)
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Figure 7: Average number of major seizures for doses of AZ66 with PTZ (80mg/kg s.c.)

Figures 6 and 7 represent the dose response of AZ66 on the number of chemically induced
seizures. In figure 6, all groups were significantly different at a p-value of .001 when compared
to the vehicle. When compared to the lone dose of 80 mg/kg subcutaneous dose of PTZ, only
the highest dose of AZ66 (30 mg/kg) proved to be significant (p<.001). Figure 7 demonstrates
the effects of increasing the dose of AZ66 on the number of major seizures. All doses of AZ66
differed from the vehicle at a p-value < .05. When the number of major seizures produced
when pretreated with AZ66 was compared to the lone dose of the s.c. 80 mg/kg dose of PTZ,
the 20 mg/kg and the 30 mg/kg proved to be significantly different (p<.05). Both of these
graphs illustrate that as the dose of AZ66 increased so did the frequency of the seizures
increased.

IV.

Discussion

The subcutaneous 80mg/kg dose of PTZ was chosen due to the quick response time,
frequency of the seizures, and the clear distinctions between mini and major seizures.
However, the effects of AZ66 were the opposite of what we expected. When screening AZ66,
the compound actually decreased the seizure latency time while increased the number of
seizures as the dose increased. These seizures were more violent and resulted in death at the
30 mg/kg dose of AZ66.
While AZ66 may attenuate seizures induced by cocaine, it does not do so for PTZ induced
seizures. PTZ exerts its effects by acting as a GABAa receptor antagonist. GABA is one the most
important inhibitory neurotransmitters in the central nervous system (Heard, Palmer, &
Zahniser 2008) and is the target of many AEDs. Because AZ66 did not perform as expected, it is

reasonable to assume that AZ66 does not directly act on the GABA pathway. This is consistent
with the fact that cocaine indirectly induces its effects on GABA receptors through
neurotransmitters (Centonze, et al., 2002). It is likely that sigma antagonists are not be
effective in treating GABA-mediated, chemically induced seizures. This assumption is
supported by the fact that AZ66 is effective at reducing seizures induced by cocaine, but not
seizures induced by PTZ. However, because cocaine induced seizures are drug refractory, AZ66
could still prove useful in other types of epilepsy.

V.

Future Studies
Futures studies for this project are needed. First off, AZ66 needs to be tested for

efficacy in reducing electrically induced seizures using the Maximal Electroshock seizure test. It
is necessary to perform this test to rule out the possibility of AZ66’s antiepileptic effects in a
different seizure type. While AZ66 is not effective in attenuating seizures caused by chemical
stimulation, it may be beneficiary in electrically kindled seizures. From there, PTZ and MES
induced convulsion tests should be run on selective antagonists for both sigma 1 and sigma 2
receptors to find which is responsible for the increase of the convulsions seen when using the
non-selective sigma antagonist AZ66.
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